Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors
Arthritis Care & Research · 2024-07 · 76 (7) · 1037-1044
DOI: 10.1002/acr.25318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 18.03.2024. Verfasst von Eric T Roberts und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco. Hauptthemen laut MEDLINE: Latent Tuberculosis, Antirheumatic Agents, Janus Kinase Inhibitors, Mass Screening. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, AHRQ HHS, National Institute for Arthritis and Musculoskeletal and Skin Diseases, NIH.
Abstract (Originalsprache)
Objective
We combined claims and electronic health record (EHR) data to provide contemporary and accurate estimates of latent tuberculosis (TB) screening among new users of a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) and assess potential gaps in testing by drug type, patient characteristics, and practice.
Methods
Our denominator population was patients in the Rheumatology Informatics System for Effectiveness (RISE) registry and Medicare using a b/tsDMARD in 2018 without a claim or prescription in the year prior. TB screening was assessed in both Medicare and RISE 1 and 3 years before the medication start date. We calculated the proportion screened overall, by medication class, and by practice. We tested for demographic differences in screening using logistic regression.
Results
In the year before drug starts, 65.6% of patients had any TB screening; in a 3‐year window, 72.9% had any TB screening. Rates of screening within 1 year by drug type were greater or equal to the overall screening rate for most drugs except for JAK inhibitors (JAKis) (46%) and interleukin‐17 inhibitors (IL‐17is) (11.5%). A lower proportion of Hispanic and Asian patients were screened compared with White patients. Practice screening rates ranged from 20.0% to 92.9% of patients within 1 year.
Conclusion
We report higher screening rates than have previously been published because of combining claims and EHR data. However, important safety gaps remain, namely, reduced screening among new users of a JAKi or IL‐17i and among Asian and Hispanic patients, as well as low‐performing practices. Educational initiatives, team‐based care delivery, task shifting, and technological interventions to address observed gaps in patient safety procedures are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, San Francisco.
- University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California.
- University of California, San Francisco, and Zuckerberg San Francisco General Hospital, San Francisco, California.
ORCID-Profile: Eric T Roberts, Gabriela Schmajuk, Jing Li, Jinoos Yazdany
Förderung
- NIAMS NIH HHS
- AHRQ HHS
- National Institute for Arthritis and Musculoskeletal and Skin Diseases, NIH
- Agency for Healthcare Research and Quality
Zitieren
APA
Roberts, E. T., Schmajuk, G., Li, J., Murrill, M., & Yazdany, J. (2024). Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors. Arthritis Care & Research, 76(7), 1037-1044. https://doi.org/10.1002/acr.25318
Vancouver
Roberts ET, Schmajuk G, Li J, Murrill M, Yazdany J. Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors. Arthritis Care & Research. 2024;76(7):1037-1044. doi:10.1002/acr.25318
BibTeX
@article{Roberts2024,
author = {Roberts, Eric T and Schmajuk, Gabriela and Li, Jing and Murrill, Matthew and Yazdany, Jinoos},
title = {Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors},
journal = {Arthritis Care & Research},
year = {2024},
volume = {76},
number = {7},
pages = {1037--1044},
doi = {10.1002/acr.25318}
}
EUVIMED